Microvesicles from Lactobacillus reuteri (DSM-17938) completely reproduce modulation of gut motility by bacteria in mice

PLoS One. 2020 Jan 7;15(1):e0225481. doi: 10.1371/journal.pone.0225481. eCollection 2020.

Abstract

Microvesicles are small lipid, bilayer structures (20-400 nm in diameter) secreted by bacteria, fungi, archaea and parasites involved in inter-bacterial communication and host-pathogen interactions. Lactobacillus reuteri DSM-17938 (DSM) has been shown to have clinical efficacy in the treatment of infantile colic, diarrhea and constipation. We have shown previously that luminal administration to the mouse gut promotes reduction of jejunal motility but increases that in the colon. The production of microvesicles by DSM has been characterized, but the effect of these microvesicles on gastrointestinal motility has yet to be evaluated. To investigate a potential mechanism for the effects of DSM on the intestine, the bacteria and its products have here been tested for changes in velocity, frequency, and amplitude of contractions in intact segments of jejunum and colon excised from mice. The effect of the parent bacteria (DSM) was compared to the conditioned media in which it was grown, and the microvesicles it produced. The media used to culture the bacteria (broth) was tested as a negative control and the conditioned medium was tested after the microvesicles had been removed. DSM, conditioned medium, and the microvesicles all produced comparable effects in both the jejunum and the colon. The treatments individually decreased the velocity and frequency of propagating contractile cluster contractions in the jejunum and increased them in the colon to a similar degree. The broth control had little effect in both tissues. Removal of the microvesicles from the conditioned medium almost completely eradicated their effect on motility in both tissues. These results show that the microvesicles from DSM alone can completely reproduce the effects of the whole bacteria on gut motility. Furthermore, they suggest a new approach to the formulation of orally active bacterial therapeutics and offer a novel way to begin to identify the active bacterial components.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell-Derived Microparticles / metabolism*
  • Colic / metabolism
  • Colic / microbiology
  • Colon / microbiology
  • Constipation / metabolism
  • Constipation / microbiology
  • Diarrhea / metabolism
  • Diarrhea / microbiology
  • Gastrointestinal Motility / genetics
  • Humans
  • Jejunum / metabolism
  • Jejunum / microbiology
  • Limosilactobacillus reuteri / metabolism*
  • Mice
  • Probiotics / metabolism*

Grants and funding

This study was funded in part by an unrestricted grant in support of research from BioGaia (Stockholm, Sweden). BioGaia was not involved in any way in the study design, conduct or execution of the study, data collection and analysis, or preparation of the manuscript. The study was also funded by the Natural Sciences and Engineering Research Council Canada (NSERC) #2014-05517 by a grant awarded to WAK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.